Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

BACKGROUND: Temsirolimus, a selective inhibitor of the mammalian target of rapamycin, has demonstrated clinical benefit versus investigator’s choice (INV) of therapy in patients with relapsed/refractory mantle cell lymphoma (MCL). METHODS: This post hoc study retrospectively assigned simplified Mant...

Descripción completa

Detalles Bibliográficos
Autores principales: Hess, Georg, Coiffier, Bertrand, Crump, Michael, Gisselbrecht, Christian, Offner, Fritz, Romaguera, Jorge, Kang, Lisa, Moran, Pádraig J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416347/
https://www.ncbi.nlm.nih.gov/pubmed/25938001
http://dx.doi.org/10.1186/s40164-015-0006-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416347/
https://www.ncbi.nlm.nih.gov/pubmed/25938001
http://dx.doi.org/10.1186/s40164-015-0006-1

Ejemplares similares